anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition containing tachioside or 9,12,13-trihydroxy-10(E)-octadecenoic acid is provided to suppress differentiation of adipocyte precursor cells and fat accumulation. CONSTITUTION: A composition for treating obesity contains tachioside or 9,12,13-trihydroxy-10(E)-octadecenoic acid as an active ingredient, isolated from wheat bran extract. Tachioside is isolated from sugarcane molasses, Berchemia racemosa, or bamboo culm. The compound is isolated from licorice and Colocasia antiquorum. The composition also contains a food composition and pharmaceutical composition. A composition for treating insulin resistance contains the tachioside or 9,12,13-trihydroxy-10(E)-octadecenoic acid as an active ingredient.
BACKGROUND: Chronic comorbid conditions are common in patients with sepsis and may affect the outcomes. This study aimed to evaluate the prevalence and outcomes of common comorbidities in patients with sepsis.
METHODS: We conducted a nationwide retrospective cohort study. Using data from the National Health Insurance Service of Korea. Adult patients (age ≥ 18 years) who were hospitalized in tertiary or general hospitals with a diagnosis of sepsis between 2011 and 2016 were analyzed. After screening of all International Classification of Diseases 10th revision codes for comorbidities, we identified hypertension, diabetes mellitus (DM), liver cirrhosis (LC), chronic kidney disease (CKD), and malignancy as prevalent comorbidities.
RESULTS: Overall, 373,539 patients diagnosed with sepsis were hospitalized in Korea between 2011 and 2016. Among them, 46.7% had hypertension, 23.6% had DM, 7.4% had LC, 13.7% had CKD, and 30.7% had malignancy. In-hospital mortality rates for patients with hypertension, DM, LC, CKD, and malignancy were 25.5%, 25.2%, 34.5%, 28.0%, and 33.3%, respectively, showing a decreasing trend over time (P < 0.001). After adjusting for baseline characteristics, male sex, older age, use of mechanical ventilation, and continuous renal replacement therapy, LC, CKD, and malignancy were significantly associated with in-hospital mortality.
CONCLUSIONS: Hypertension is the most prevalent comorbidity in patients with sepsis, and it is associated with an increased survival rate. Additionally, liver cirrhosis, chronic kidney disease, and malignancy result in higher mortality rates than hypertension and DM, and are significant risk factors for in-hospital mortality in patients with sepsis.
Micro-particle phase is new and has new properties. The patent refers to utilization of micro-particle phase in cosmetic compositions, especially of make-up type, having property of reducing or suppressing the defects of keratin matter and/or modifying the perception of volume of certain regions of this matter. Micro-particle-phase comprises micro-particles having average dimensions 5-100 (preferably 20-50) microns and at least two consecutive faces whose normals form angle at least 90 (preferably 90-175) degrees at median point. The micro-particles preferably have at least two consecutive faces with non-parallel planes, having apex angle between them up to 90 (preferably 5-90) degrees, and refraction index above 1, preferably 1.25-1.9, and especially 1.45-1.55. Micro-particle phase can be of polymeric or of metal oxide type, and amounts to 0.5-30 (preferably 2-15) wt.% per total wt. of cosmetic composition, which has form of emulsion with oil phase comprising at least one volatile silicone oil, preferably cyclomethicone (sic), in amount at least 5 (preferably 25-95) wt.%, and optionally volatile isoparaffin, and also optional pastes, gums, waxes and oils of vegetable, mineral, animal or synthetic origin.  Independent claims are also included for: (1) Cosmetic composition comprising, on cosmetically acceptable support, micro-particle phase as claimed, oil phase as claimed, aqueous phase, and/or one or more surfactants and/or thickening agents, optional mineral or organic pigments, varnishes and colorants soluble in water or organic media, antioxidants, perfumes, essential oils, preservatives, components with cosmetic or dermatological activity, liposoluble polymers and dispersions of polymer particles in aqueous or non-aqueous media, and having form of simple or complex emulsion, aqueous gel, anhydrous or hydro-alcoholic, serum, powder, paste, solid stick or aerosol-conditioned mousse or spray; and (2) non-therapeutic treatment of keratin tissue (skin, eyelashes, lips etc.) with cosmetic composition as claimed, comprising the application of composition in order of limiting, diminishing or suppressing natural imperfections and/or modify the volume perception of certain regions.
Patients should be counseled that antibacterial drugs including UNASYN should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When UNASYN is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by UNASYN or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibacterial which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterial, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible.
Turner syndrome (TS) is a common chromosomal disorder that affects approximately 1 in 2500 live female births. Complete or partial monosomy of one of the X chromosomes in a female is associated with various congenital heart defects (CHDs), which include aortic dilatation, coarctation of aorta and BAV. Congenital cardiovascular defects related to CHD are the leading cause of death in women with TS. The Turner Syndrome Network Registry (TRN Registry) and genetic sample repository can address gaps in knowledge of CHD in TS by facilitating the recognition of demographic and genetic patterns. TRN Registry-based research can improve surveillance of TS patients who are at risk for CHD and provide valuable insight into genetic components of CHD.

The investigators will recruit TS patients into the TRN Registry and obtain blood and/or saliva samples after informed consent. The genetic diagnosis of TS will be confirmed using chromosomal microarrays. The array data will be also be used to identify genomic copy number variants, and rare variants in protein coding genes will be determined by exome sequencing. The investigators will derive induced pluripotent stem cells from some participants to determine why CHD is so prevalent in TS. CHD risk genes will be identified in comparisons between TS cases with and without congenital heart defects. To facilitate these comparisons, the investigators will abstract the demographic and medical data of registry participants from questionnaires and medical records. Imaging will be used to confirm the diagnosis of CHD and to determine the prevalence and severity of additional cardiovascular defects.
Patients randomized to the immediate switch group continued treatment with donepezil through the evening prior to Day 8 of the study. On Day 8, all patients began open-label treatment with 5 cm\^2 rivastigmine patch formulation. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm\^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm\^2 patch and continued on their best tolerated dose for the remainder of the study.
Patients with subjective complaints of xerostomia will be given a screening questionnaire to complete. If they meet the criteria on this screening form, the research coordinator will be notified and will meet with the patient either immediately or at a scheduled follow-up appointment. The research coordinator will review the information and then explain the details of the study to the patient and obtain informed consent. Once the patient has signed the informed consent, the research coordinator will collect the demographic, medical history, and contact information from the patient. Any information missing will be noted for follow-up investigation by the research coordinator. If a subject is of child bearing age, they will be asked to complete a urine pregnancy test prior to enrollment.\[a\] First appointment -Screening, consent. \[b\]Follow appointments- review, then Patients will do VAS questionnaire, QOL questionnaire, Sialometry will be done measuring unstimulated whole saliva and Stimulated whole saliva for 5 min each.
Subjects will receive 12 sham acupuncture treatments (delivered twice a week) over 6 weeks. The sham needle is blunted needle whose shaft telescopes into the handle when tapped. While the needle appears to have been inserted, it does not actually penetrate the skin. It is held in place by the same standard guide tube used in the true acupuncture group. The acupuncture points and duration of treatment are the same as for the true acupuncture group.
In a method, a first type of health data is collected over n days and a second type of health data is collected over m days. After n days, the average of the first type of health data is calculated. The average is normalised to produce a first sub-score. An aggregate health score is updated with the first sub-score. After m days, the average of the second type of health data is calculated. The average is normalised to produce a second sub-score. The aggregate health score is updated with the second sub-score. The process is repeated by varying n and m at each instance, in which n and m are each selected at random.
Findings on the association between abdominal obesity and hip fracture were summarized in a meta-analysis in 2017; however, no study has examined the dose-response association between abdominal fat indices and hip fracture. Also, we found no meta-analysis investigating other types of bone fractures including any vertebral fractures in relation to abdominal obesity. Therefore, the present systematic review and dose-response meta-analysis of prospective cohort studies were conducted to examine the association between abdominal obesity and different types of bone fractures. A comprehensive literature search was done by searching PubMed, Scopus, Web of Science, and Google Scholar until October 2021. In total, 23 articles from prospective cohort studies with a total sample size of 3,456,631 participants were included. During the follow-up periods ranging between 4 and 26 years, 137,989 cases of bone fracture were recorded. After comparing the highest and lowest categories of abdominal fat indices, the summary relative risks (RRs) of any, hip, and vertebral fractures were 0.99 (95% CI: 0.81-1.20), 1.09 (95% CI: 0.82-1.43), and 1.18 (95% CI: 1.05-1.33), respectively, indicating a significant positive association between abdominal obesity and risk of vertebral fracture. In the non-linear dose-response analysis, abdominal obesity based on the waist-to-hip ratio (WHR) was positively associated with an increased risk of hip fracture from 0.7 to 1.1 units of WHR. In the linear analysis, a 10 cm increase in waist circumference (WC) was associated with a 3% higher risk of vertebral fracture. We found no other dose-response association for other types of bone fractures. In conclusion, abdominal obesity may be associated with a higher risk of hip and vertebral fractures.
BACKGROUND: Among older people undiagnosed and untreated vision impairment and blindness are common. The leading causes are uncorrected refractive errors and cataracts. Vision problems are associated with a lower quality of life, several health problems, and a higher chance of falling accidents and fractures. To eliminate avoidable vision impairment and blindness, targeted eye screening programs are recommended. Older patients, receiving home healthcare, have not yet been considered as a population at risk who could benefit from eye screening.
METHODS: A cluster-randomized controlled trial will be conducted to investigate the cost-effectiveness and cost-utility of online nurse-assisted eye screening in home healthcare, compared to care as usual, in reducing avoidable vision impairment. A healthcare and societal perspective will be used. The study will be performed in collaboration with several home healthcare organizations in the Netherlands. The online eye screening consists of near and distance visual acuity, followed by an Amsler grading test. Measurements in both groups will take place at baseline and after 6 and 12 months of follow-up. A total of 240 participants will be recruited. Older men and women (65 +), who receive home-based nursing and are cognitively able to participate, will be included. The primary outcome will be the change of two lines or more on the Colenbrander-1 M visual acuity chart between baseline and 12-month follow-up.
DISCUSSION: An eye screening for populations at risk contributes to the detection of undiagnosed and untreated vision impairment. This may reduce the health-related consequences of vision loss and the high economic burden associated with vision impairment.
TRIAL REGISTRATION: ClinicalTrials.gov NCT06058637. Registered on 27 September 2023.
Despite being the world's top risk factor for death and disability, hypertension awareness and control within the chronic kidney disease (CKD) population have decreased. This is particularly important considering the heightened severity and management challenges of hypertension in CKD patients, whose outcomes are often worse compared with persons with normal kidney function. Therefore, finding novel therapeutics to improve blood pressure control within this vulnerable group is paramount. Although medications that target the renin-angiotensin-aldosterone system remain a mainstay for blood pressure control in most stages of CKD, we discuss novel approaches that may expand their use in advanced CKD. We also review newer tools for blood pressure management that have emerged in recent years, including aldosterone synthase inhibitors, endothelin receptor antagonists, and renal denervation. Overall, the future of hypertension management in CKD appears brighter, with a growing arsenal of tools and a deeper understanding of this complex disease.
Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported.In pooled safety population, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered. Fatal cardiac failure was reported in <1% of patients.

In the adjuvant treatment of RCC study, 11 patients experienced Grade 2 decreased ejection fraction (left ventricular ejection fraction [LVEF] 40% to 50% and a 10% to 19% decrease from baseline). In 3 of these 11 patients, the ejection fractions arm did not return to ≥50% or baseline by the time of last measurement. No patients who received sunitinib malate were diagnosed with CHF. 

Patients who presented with cardiac events within 12 months prior to sunitinib malate administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from sunitinib malate clinical studies. Patients with prior anthracycline use or cardiac radiation were also excluded from some studies. It is unknown whether patients with these concomitant conditions may be at a higher risk of developing left ventricular dysfunction.

Consider monitoring LVEF at baseline and periodically as clinically indicated. Carefully monitor patients for clinical signs and symptoms of congestive heart failure (CHF). Discontinue sunitinib malate capsules in patients who experience clinical manifestations of CHF. Interrupt sunitinib malate and/or reduce the dose in patients without clinical evidence of CHF who have an ejection fraction of greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline ejection fraction was not obtained.
Patients are randomized to receive aminophylline or placebo for 72 hours, in a blinded fashion. Serum theophylline levels monitor for safety of aminophylline dose. Goal theophylline levels is 5-7 mcg/ml. Laboratory results will be faxed directly to the pharmacy who will adjust subsequent aminophylline dosing to maintain appropriate theophylline levels. Urine output and serum creatinine levels will be monitored to assess acute kidney injury. Serum Neutrophil Gelatinase Associated Lipocalin (NGAL) levels will also be monitored.
The invention relates to infantile indigestion-eliminating tea and a preparation method therefor. The infantile indigestion-eliminating tea is prepared from the following raw materials in parts by weight: 8-10 parts of hawthorns, 4-6 parts of semen raphani, 5-7 parts of endothelium corneum gigeriae galli, 3-4 parts of medicated leavens, 3-5 parts of malts, 4-5 parts of rice sprouts, 8-14 parts of juicy peaches, 10-14 pars of pumpkins, 7-9 parts of raisin and a proper amount of fresh green tea leaves and tannase. By using the fresh green tea leaves as a raw material, the fresh green tea leaves are blanched to effectively reduce the caffeine component in the tea leaves. Both the hawthorns and semen raphani added into the tea play the roles of promoting digestion and removing stasis. Moreover, endothelium corneum gigeriae galli, medicated leavens, malts and rice sprouts are further added to moisten the spleen, promote digestion and remove stasis. The tea provided by the invention is mild in solution property, aromatic and palatable in taste, and suitable for infants to drink.
BACKGROUND: Neuroinflammation represents the immune response of the central nervous system to nerve injury, infection, toxin stimulation, or autoimmunity and is implicated in a wide range of neurological disorders. Viruses play a pivotal role as extrinsic biological drivers in neuroinflammation; however, numerous aspects remain unexplored. In this study, we employed bibliometric analysis to assess the current status of viral research in neuroinflammation and anticipate future research directions and emerging trends.
METHODS: Conduct a comprehensive search for scholarly publications within the Web of Science Core Collection database, with search terms on neuroinflammation and virus. Apply Microsoft Excel Office, Hiplot, R (version 4.3.1), VOSviewer (version 1.6.20) and CiteSpace (6.2.R6, advanced) software for the bibliometric analysis and visualization.
RESULTS: A total of 4230 articles and reviews on virus and neuroinflammation were identified, demonstrating a consistent upward trend over time. The United States was the country that contributed the most publications. Approximately 22274 authors from 4474 institutions contributed to the research. Johns Hopkins University leads with the highest number of publications and citations. The top three authors with the most published articles on this field are Power, C., Lane, T. E., and Buch, S. The Journal of Neuroinflammation is the most authoritative choice for researchers. The main research focuses in this field include multiple sclerosis, Parkinson's disease, blood-brain barrier, COVID-19, Alzheimer's disease, gene therapy. In recent years, stress have emerged as hot keywords, particularly depression, human immunodeficiency virus-associated neurocognitive disorders, blood-brain barrier, gut microbiota related directions, indicating a potential shift in research focus.
CONCLUSION: Research on the virus and neuroinflammation has attracted increasing attention in the past decade. European and American countries have been pivotal in conducting research on virus and neuroinflammation, while China has produced a significant number of publications, its impact is still limited. Stress is likely to emerge as the next area of focus in this field. The association and regulation between viral infection and psychiatric disorders are not fully understood, and further research is needed to explore the role of neuroinflammation caused by different types of viral infection and psychiatric disorders.
In a patient record identification apparatus, at least one query value relating to at least one medical condition is input (210). Patient records are received (220) from a patient database. Each patient record includes at least one attribute value relating to the at least one medical condition, and each patient record includes information relating to an outcome of the at least one medical condition. A first set of patient records is determined (230) based on a similarity between the at least one query value input by the user and the at least one attribute value for the patient records. The first set of patient records is separated (240) into patient records relating to a positive outcome and into patient records relating to a negative outcome. An implemented model calculates (250) at least one outcome probability for the at least one medical condition for each patient record of the first set of patient records based on the at least one attribute value for each patient record of the first set of patient records. A second set of patient records is determined (260) from the first set of patient records including a number of patient records in a first sub-set of the patient records relating to the positive outcome and a number of patient records in a second sub-set of the patient records relating to the negative outcome and the at least one outcome probability for the at least one medical condition for each patient record of the first sub-set and second sub-set of the patient records.
A computer-implemented method and system facilitating a karaoke performance while exercising during an individual exercise session or group exercise class are disclosed. An indication of a song to be performed during the session or exercise class is received. At least one computer-readable karaoke file corresponding to the song is retrieved. The at least one computer-readable karaoke file may comprise common data elements, at least two independent karaoke data streams and exercise-related data elements. From a first class participant a selection of a first data stream of the at least two independent karaoke data streams is received. From a second class participant a selection of a second data stream of the at least two independent karaoke data streams is received. The presentation of the common data elements and the exercise-related data elements on a display common to the first and the second class participants is directed. The presentation of the first karaoke data stream on a display unique to the first class participant is directed. The presentation of the second karaoke data stream on a display unique to the second class participant is directed. The presentation of the common data elements, the exercise-related data elements, the first data stream and the second data stream may be synchronized.